1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cyxone AB (publ)

Cyxone AB (publ)

CYXO.ST
Cyxone AB (publ)SE flagStockholm Stock Exchange
0.02
SEK
- -
- -
6.75MMarket Cap
Cyxone AB (publ)
CYXO.ST
(Stockholm Stock Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
-0.4
-0.75
-0.34
-0.72
-0.65
-0.4
-0.2
-0.11
Basic EPS, GAAP
- -
- -
-0.52
-1.03
-0.35
-0.66
-0.63
-0.47
-0.22
-0.12
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.53
-1.15
-1.03
-1.49
-2.09
-1.77
-1.75
-1.12
Book Value per Share
- -
- -
1.35
0.81
1.17
0.77
0.36
0.26
0.13
0.02
Tangible Book Value per Share
- -
- -
22
42
51
68
70
105
116
194
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
1
1
2
2
2
3
3
Depreciation Expense
- -
- -
-9
-32
-17
-49
-45
-42
-23
-22
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
21
30
34
60
52
25
26
14
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
LT Debt
- -
23
37
48
72
67
39
47
39
30
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
237
237
237
Market Capitalization
10
11
19

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
19
13
7
Cash, Cash Equivalents & STI
18
12
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
4
3
Payables & Accruals
- -
- -
- -
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.04%
-17.01%
Free Cash Flow
- -
10.92%
-47.51%
Net Income, GAAP
- -
15.79%
-45.87%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.17
-0.12
-0.1
- -
-0.4
2023
-0.05
-0.05
-0.05
- -
-0.2
2024
-0.02
-0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Rallybio Corporation (RLYB)
Agentix Corp. (AGTX)
Passage Bio, Inc. (PASG)
Mesoblast Limited (MEOBF)
PaxMedica, Inc. Common Stock (PXMD)
TAKE Solutions Limited (TAKE.NS)
Business
Cyxone AB (publ) (Ticker: CYXO.ST) operates as a clinical-stage biotechnology company focused on developing disease-modifying therapies for autoimmune and autoinflammatory diseases, including rheumatoid arthritis and multiple sclerosis. The company's pipeline centers on two primary drug candidates: Rabeximod, an oral small molecule in phase II clinical development targeting patients with inadequate response to TNF-alpha inhibitors in rheumatoid arthritis by modulating pro-inflammatory cells; and T20K, a cyclotide-based drug candidate that has completed phase I studies and targets cytokine inhibition for multiple sclerosis and other autoimmune disorders. Founded in 2015 and headquartered in Malmö, Sweden, Cyxone conducts operations primarily in Europe through its Swedish base and affiliated entities such as Cyxone Switzerland AG. In 2024, the company shifted its rabeximod strategy toward smaller exploratory studies in TNF-alpha non-responders following consultations with key opinion leaders, identified and confirmed its biological target protein independently, and launched a rights issue in July-August targeting SEK 23 million to fund these programs and T20K advancement, though it subscribed to only about 27% yielding roughly SEK 6.3 million net. Facing liquidity shortfalls, Cyxone received payment demands including a disputed SEK 5 million milestone, trading was halted, shares were delisted from Nasdaq First North, and the company filed for bankruptcy in early December 2024 with proceedings declared by the Malmö court.